{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:45:21Z","timestamp":1788911121980,"version":"build-2803163510"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Older (\u226550 years of age [YoA]) and immunocompromised adults are at higher risk of herpes zoster (HZ). Those with comorbidities are also at increased risk, however, recent US evidence is lacking, especially among 18\u201349 YoA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This US retrospective cohort study (2015\u20132022, Merative MarketScan Commercial and Medicare Supplemental) compared HZ incidence rates (IRs) in younger immunocompetent adults (18\u201349 YoA) with comorbidities (asthma, chronic kidney disease [CKD], chronic obstructive pulmonary disease [COPD], depression, diabetes, stress, and trauma) versus immunocompetent adults 50\u201359 YoA without comorbidities. Adjusted HZ IR ratios (aIRRs) versus 50\u201359 YoA adults were compared using a predetermined 0.62 non-inferiority margin for the aIRR 95% confidence interval lower limit (95% CI LL). aIRRs were classified as comparable (aIRR 95% CI LL &amp;gt; 0.62 and \u22641.0), significantly higher (aIRR 95% CI LL &amp;gt; 1.0), or inconclusive (any other result). HZ case: diagnostic code B02.2x plus oral antiviral \u00b17 days. Sensitivity analyses investigated HZ IRs by number of comorbid conditions (1, 2, or \u22653).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HZ IRs were significantly higher (aIRR 95% CI LL &amp;gt; 1.0) from 30 to 39 YoA (aIRR; 95% CI) in asthma (1.19; 1.10\u20131.29), COPD (1.31; 1.22\u20131.40), depression (1.31; 1.22\u20131.40), diabetes (1.18; 1.06\u20131.32), stress (1.28; 1.11\u20131.47), and trauma (1.25; 1.17\u20131.34) populations than immunocompetent 50\u201359 YoA and from 50 to 59 YoA in CKD (1.50; 1.28\u20131.77). In sensitivity analyses, HZ IR appeared to increase with more comorbid conditions and age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study found that younger adults (30+ YoA) with certain comorbidities have a higher HZ risk than immunocompetent 50\u201359 YoA adults.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciag095","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:28:39Z","timestamp":1774582119000},"page":"e1375-e1383","source":"Crossref","is-referenced-by-count":2,"title":["Age-Specific Risk of Herpes Zoster in Adults Aged \u226518 Years With Comorbid Conditions\u2014A Retrospective Cohort Study in the United States"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1586-3549","authenticated-orcid":false,"given":"Rachel A","family":"Cohen","sequence":"first","affiliation":[{"name":"GSK , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1921-7626","authenticated-orcid":false,"given":"Driss","family":"Oraichi","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6576-1981","authenticated-orcid":false,"given":"Agnes","family":"Mwakingwe-Omari","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3836-8083","authenticated-orcid":false,"given":"Bruno","family":"Anspach","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"Curran","sequence":"additional","affiliation":[{"name":"GSK , Wavre ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0158-1797","authenticated-orcid":false,"given":"Huifeng","family":"Yun","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"2026070722324375700_ciag095-B1","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"2026070722324375700_ciag095-B2","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"2026070722324375700_ciag095-B3","first-page":"1432","article-title":"Herpes zoster and postherpetic neuralgia: prevention and management","volume":"83","author":"Fashner","year":"2011","journal-title":"Am Fam Physician"},{"key":"2026070722324375700_ciag095-B4","doi-asserted-by":"crossref","first-page":"ofaa005","DOI":"10.1093\/ofid\/ofaa005","article-title":"Risk factors for herpes zoster infection: a meta-analysis","volume":"7","author":"Marra","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026070722324375700_ciag095-B5","author":"Food and Drug Administration (FDA) Center for Biologics Evaluation and Research"},{"key":"2026070722324375700_ciag095-B6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026070722324375700_ciag095-B7","author":"Food and Drug Administration (FDA) Center for Biologics Evaluation and Research"},{"key":"2026070722324375700_ciag095-B8","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/ajt.16649","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged &gt;19 years: recommendations of the advisory committee on immunization practices\u2014United States, 2022","volume":"22","author":"Anderson","year":"2022","journal-title":"Am J Transpl"},{"key":"2026070722324375700_ciag095-B9","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s13555-021-00535-7","article-title":"Burden of herpes zoster in adult patients with underlying conditions: analysis of German claims data, 2007\u20132018","volume":"11","author":"Batram","year":"2021","journal-title":"Dermatol Ther"},{"key":"2026070722324375700_ciag095-B10","doi-asserted-by":"crossref","first-page":"ofae535","DOI":"10.1093\/ofid\/ofae535","article-title":"Burden of herpes zoster in individuals with chronic conditions in the Republic of Korea: a nationwide population-based database study","volume":"11","author":"Chen","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026070722324375700_ciag095-B11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/vaccines8010020","article-title":"The unknown health burden of herpes zoster hospitalizations: the effect on chronic disease course in adult patients \u226550 years","volume":"8","author":"Piazza","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"2026070722324375700_ciag095-B12","doi-asserted-by":"crossref","first-page":"E46","DOI":"10.5888\/pcd21.240109","article-title":"Chronic disease indicators: 2022\u20132024 refresh and modernization of the web tool","volume":"21","author":"Watson","year":"2024","journal-title":"Prev Chronic Dis"},{"key":"2026070722324375700_ciag095-B13","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.5888\/pcd21.230267","article-title":"Chronic disease prevalence in the US: sociodemographic and geographic variations by zip code tabulation area","volume":"21","author":"Benavidez","year":"2024","journal-title":"Prev Chronic Dis"},{"key":"2026070722324375700_ciag095-B14"},{"key":"2026070722324375700_ciag095-B15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12913-018-3148-0","article-title":"Identifying diabetes cases from administrative data: a population-based validation study","volume":"18","author":"Lipscombe","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"2026070722324375700_ciag095-B16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6947-12-38","article-title":"Developing an algorithm to identify people with chronic obstructive pulmonary disease (COPD) using administrative data","volume":"12","author":"Smidth","year":"2012","journal-title":"BMC Med Inform Decis Mak"},{"key":"2026070722324375700_ciag095-B17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/1062860606288243","article-title":"Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease, and depression","volume":"21","author":"Solberg","year":"2006","journal-title":"Am J Med Qual"},{"key":"2026070722324375700_ciag095-B18","doi-asserted-by":"crossref","first-page":"e017474","DOI":"10.1136\/bmjopen-2017-017474","article-title":"Validation of asthma recording in the Clinical Practice Research Datalink (CPRD)","volume":"7","author":"Nissen","year":"2017","journal-title":"BMJ Open"},{"key":"2026070722324375700_ciag095-B19","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ndt\/gfr598","article-title":"Validating a case definition for chronic kidney disease using administrative data","volume":"27","author":"Ronksley","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2026070722324375700_ciag095-B20","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/infdis\/jis937","article-title":"Association of physical trauma with risk of herpes zoster among Medicare beneficiaries in the United States","volume":"207","author":"Zhang","year":"2013","journal-title":"J Infect Dis"},{"key":"2026070722324375700_ciag095-B21","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026070722324375700_ciag095-B22","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"2026070722324375700_ciag095-B23","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.4161\/hv.28620","article-title":"Sociodemographic characteristics and chronic medical conditions as risk factors for herpes zoster: a population-based study from primary care in Madrid (Spain)","volume":"10","author":"Esteban-Vasallo","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2026070722324375700_ciag095-B24","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.mayocp.2012.05.021","article-title":"Chronic medical conditions as risk factors for herpes zoster","volume":"87","author":"Joesoef","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"2026070722324375700_ciag095-B25","doi-asserted-by":"crossref","first-page":"g2911","DOI":"10.1136\/bmj.g2911","article-title":"Quantification of risk factors for herpes zoster: population based case-control study","volume":"348","author":"Forbes","year":"2014","journal-title":"BMJ"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag095\/67558199\/ciag095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/6\/e1375\/67558199\/ciag095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/6\/e1375\/67558199\/ciag095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:33:20Z","timestamp":1783478000000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/6\/e1375\/8542455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3,27]]},"published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag095","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,15]]},"published":{"date-parts":[[2026,3,27]]}}}